Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring them to patients globally. With growing revenues from the three resulting commercialized products, we are reinvesting in our business to maximize the potential of our pipeline, which we intend to supplement with targeted business development activities and internal drug discovery _ all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. For more information about Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter.
Biotechnology
500 - 1,000
Alameda, CA, United States
About

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring them to patients globally. With growing revenues from the three resulting commercialized products, we are reinvesting in our business to maximize the potential of our pipeline, which we intend to supplement with targeted business development activities and internal drug discovery _ all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer.

For more information about Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter.

Site Traffic
  • 939973 Global Rank
  • 181805
    United States
  • 88.1 K Estimated Visits
Traffic Sources
  • Search
    39.19%
  • Direct
    35.81%
  • Mail
    17.79%
  • Social
    6.52%
  • Referrals
    0.70%
  • Display
    0.00%
Powered by
Alexa Traffic Data
Global Rank 371,214
6,870
United Kingdom Rank 19,455
623
United Kingdom Page Views 64.7%
2.6%
Top Countries
Top Search Keywords
  • Pick
Ad Intelligence
  • Native
    0.00%
  • Standard
    100.00%
  • Direct
    0.00%
Ads Seen Recently
101
Longest Running Ad
Exelixis
Device
Mobile
Dimensions
320x50
Exelixis
Device
Mobile
Dimensions
other
Exelixis
Device
Mobile
Dimensions
300x250
Exelixis
Device
Mobile
Dimensions
other
Exelixis
Device
Desktop
Dimensions
other
Exelixis receives traffic in countries such as United States.

They are headquartered at Alameda, CA, United States, and have 4 advertising & marketing contacts listed on Kochava. Exelixis works with Advertising technology companies such as Google Remarketing, LinkedIn Ads, DoubleClick.Net, AppNexus, AppNexus Segment Pixel, Bizo, DoubleClick Bid Manager, SITO Mobile, Rocket Fuel, StackAdapt, StackAdapt Retageting, Index Exchange, Aggregate Knowledge, Neustar AdAdvisor, Media.net, Kargo, DemDex, Adobe Audience Manager Sync, TripleLift, Rubicon Project, Sharethrough, SpotX, SpotXchange, IponWeb BidSwitch, StickyAds TV, Burst Media, Openads/OpenX.